MAIA Biotechnology, Inc. (MAIA)
| Market Cap | 76.45M +1.7% |
| Revenue (ttm) | n/a |
| Net Income | -24.25M |
| EPS | -0.67 |
| Shares Out | 60.67M |
| PE Ratio | n/a |
| Forward PE | 8.00 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 541,952 |
| Open | 1.330 |
| Previous Close | 1.360 |
| Day's Range | 1.255 - 1.360 |
| 52-Week Range | 0.870 - 3.190 |
| Beta | 0.23 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 11, 2026 |
About MAIA
MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). The company was incorporated in 2018 and is headquartered in Chicago, Illinois.
Financial Performance
Financial StatementsNews
MAIA Biotechnology secures funding for clinical trial of ateganosine
MAIA Biotechnology (MAIA) announced that net proceeds from its $33M public offering of common stock in March are expected to fully fund the company’s ongoing pivotal Phase 3 clinical trial…
MAIA Biotechnology Expects Recent $33 Million Capital Raise to Fully Fund Ongoing Pivotal Phase 3 Trial of Novel Telomere-Targeting Anticancer Therapy
Strong participation in recent $33 million common stock offering highlights investor confidence in late-stage clinical momentum and commercial potential
MAIA Biotechnology Reports Overall Survival Exceeding Two Years for Eight Patients in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer
Potential breakthrough therapeutic targets $50B+ global immunotherapy market 1 CHICAGO, March 31, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a cli...
Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA)
New York, March 27, 2026 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released an update note on MAIA Biotechno...
MAIA Biotechnology Announces Closing of $30 Million Underwritten Public Offering of Common Stock
Financing included participation by healthcare-dedicated investors alongside existing shareholders CHICAGO, IL, March 04, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAI...
MAIA Biotechnology 20M share Spot Secondary priced at $1.50
acted as sole book running manager for the offering.
MAIA Biotechnology announces common stock offering, no amount given
MAIA Biotechnology (MAIA) announced that it has commenced an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to…
MAIA Biotechnology Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
CHICAGO, IL, March 02, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies ...
MAIA Biotechnology published a 2026 Letter to Shareholders
MAIA Biotechnology (MAIA) published a 2026 Letter to Shareholders by Founder and CEO Vlad Vitoc, M.D. featuring the Company’s strong momentum in clinical trials of its lead molecule, ateganosine, as…
MAIA Biotechnology's Phase 3 Momentum Demonstrates Potential Breakthrough Anticancer Opportunity in $50 Billion Immunotherapy Market
Ongoing Phase 3 full approval clinical trial of ateganosine holds high probability of technical success for interim and full analysis
MAIA Biotechnology highlights milestones, catalysts for FY26
Targeted 2026 Milestones: Initial measures of efficacy from Phase 3 study. Interim disease control rates, overall response rates and progression free survival analysis of ateganosine compared to the c...
MAIA Biotechnology Advances Ateganosine Cancer Treatment Program, Outlines Targeted 2026 Clinical Milestones and Growth Momentum
High probability of technical success in pivotal Phase 3 trial based on unmatched efficacy data for third-line non-small cell lung cancer (NSCLC) treatment
MAIA Biotechnology directors participate in private placement financings
MAIA Biotechnology (MAIA) announced that independent directors including Adelina Louie Ngar Yee and Stan Smith, purchased common stock and warrants in the recent private placement offering which close...
MAIA Biotechnology Board Members Continue to Participate in Private Placement Financings
Purchases reflect strong confidence in the scientific differentiation and commercial potential of ateganosine CHICAGO, Dec. 24, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) ...
MAIA Biotechnology to sell 1.233M shares at $1.22 in private placement
MAIA Biotechnology (MAIA) announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 1.233M shares of common stock at a purchase price of…
MAIA Biotechnology announces $1.51M private placement
MAIA Biotechnology (MAIA) announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 1.23M shares of common stock at a purchase price of…
MAIA Biotechnology Announces $1.51 Million Private Placement
CHICAGO, IL, Dec. 16, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies f...
MAIA's Ateganosine Surges Ahead with Breakthrough Momentum as Pivotal Phase 3 Trial Initiates
CHICAGO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Ateganosine (THIO, 6-thio-2'-deoxyguanosine), a first-in-class telomere-targeting therapy under development by MAIA Biotechnology (NYSE American: MAIA), appe...
MAIA Biotechnology doses first patient in Phase 3 trial of ateganosine in NSCLC
MAIA Biotechnology (MAIA) announced that the first patient has been dosed in the company’s THIO-104 Phase 3 pivotal trial evaluating the efficacy of ateganosine administered in sequence with a checkpo...
MAIA Biotechnology CEO, board members acquire company shares
Newly filed disclosures show that CEO Dr. Vlad Vitoc and other board members acquired approximately 182,445 shares between November 21 and 28, 2025. The latest insider buying arrives as ateganosine…
MAIA Takes Aim at a $50B Immunotherapy Market with Breakthrough Telomere-Targeting Approach
CHICAGO, Dec. 10, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology (NYSE American: MAIA) – The treatment paradigm for advanced non-small cell lung cancer (NSCLC) is undergoing another shift. After a decade...
MAIA Biotechnology announces open market purchases by CEO, directors
MAIA Biotechnology (MAIA) announced that the CEO and certain members of the Company’s Board of Directors purchased approximately 182,445 shares of MAIA common stock at market price between November 21...
MAIA Biotechnology Announces Open Market Purchases by CEO and Directors
CHICAGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunothera...
MAIA Biotechnology highlights momentum of ateganosine clinical program
MAIA Biotechnology (MAIA) announced highlights from two poster presentations delivered at SITC 2025, an annual conference hosted by the Society for Immunotherapy of Cancer, held November 5-9, 2025, in...
MAIA Biotechnology Highlights Ongoing Momentum of Ateganosine Clinical Program at SITC 2025
Company confirms 12 patients enrolled in Phase 2 THIO-101 to date as expansion trial adds new countries